Biopharmaceutical company Bristol Myers Squibb (NYSE: BMY) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 5.7% year on year to $12.97 billion. The company’s full-year revenue guidance of $49.5 billion at the midpoint came in 4.3% above analysts’ estimates. Its non-GAAP profit of $2.04 per share was 27.7% above analysts’ consensus estimates.

Is now the time to buy BMY? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Bristol Myers Squibb’s second quarter results were marked by strong contributions from its growth portfolio, leading to a positive market reaction. Management credited double-digit sales increases from key products such as Reblozyl, Breyanzi, Camzyos, Opdualag, and Qvantig with driving overall business momentum. CEO Chris Boerner emphasized that disciplined execution and a broadening product mix supported both revenue and margin expansion, while Chief Financial Officer David Elkins noted that “performance is also supported by disciplined investment in growth-oriented initiatives.” The company also highlighted progress in its oncology and cardiovascular franchises, demonstrating resilience across both new and legacy assets.

Looking ahead, Bristol Myers Squibb’s updated guidance is underpinned by continued strength from its growth portfolio and a pipeline poised for multiple pivotal readouts in the coming quarters. Management expects upcoming data from drugs like admilparant and iberdomide to open new revenue streams, while pivotal studies for therapies targeting pulmonary fibrosis, lupus, and Alzheimer’s psychosis could further expand the company’s addressable markets. CFO David Elkins stated, “We have slightly increased our projected operating expenses for the year to account for accelerated prelaunch activities supporting our CELMoDs, iberdomide and mezigdomide, the expanding pumitamig development program, and opportunities to further support the growth portfolio.”

Key Insights from Management’s Remarks

Management attributed the quarter’s performance to robust uptake in newly launched therapies, resilience in its legacy business, and operational improvements supporting profitability.

• Growth portfolio momentum: Sales of newer products such as Reblozyl, Breyanzi, Camzyos, Opdualag, and Qvantig grew at double-digit rates, with Qvantig annualizing over $1 billion and gaining market share in oncology.
• Legacy assets show resilience: Eliquis continued to deliver strong demand-driven growth, offsetting declines elsewhere in the legacy portfolio, while Revlimid revenue remained stable despite full generic competition in the U.S.
• Pipeline advances in oncology: Positive Phase III data for mezigdomide in multiple myeloma and advancing antibody-drug conjugate (ADC) programs in solid tumors highlighted the company's progress in developing next-generation oncology treatments.
• Operational efficiency and AI integration: The company expanded the use of artificial intelligence across research and enterprise operations, supported by new partnerships with Anthropic and NVIDIA, to accelerate drug discovery and decision-making.
• Financial flexibility maintained: Continued productivity initiatives and strong free cash flow enabled ongoing investment in growth assets, business development opportunities, and returns to shareholders via dividends.

Drivers of Future Performance

Management’s outlook for the remainder of the year centers on the launch of new products, key clinical trial readouts, and continued operational discipline.

• Upcoming pivotal data readouts: The company anticipates late-2026 results from key clinical programs, including admilparant for pulmonary fibrosis and iberdomide for multiple myeloma, which management believes could drive significant growth if successful.
• Expansion of growth portfolio: Continued uptake and market penetration of recently launched therapies—particularly in oncology and cardiovascular—are expected to be the main contributors to revenue, as legacy assets face increasing generic competition.
• R&D investments and risk management: Management is prioritizing disciplined resource allocation, including increased prelaunch activities for new drugs and integration of AI to enhance R&D productivity, while acknowledging that event-driven study timelines and regulatory review processes pose inherent risks.

Catalysts in Upcoming Quarters

Over the coming quarters, the StockStory team will closely monitor (1) pivotal clinical trial readouts for admilparant in pulmonary fibrosis and iberdomide in multiple myeloma, (2) the continued adoption of new therapies like Qvantig, Breyanzi, and Camzyos in core markets, and (3) the impact of AI integration on R&D productivity and the efficiency of clinical development. Progress on these fronts will be central to Bristol Myers Squibb’s ability to sustain momentum and deliver on upgraded guidance.

Bristol-Myers Squibb currently trades at $64.92, up from $63.41 just before the earnings. In the wake of this quarter, is it a buy or sell? See for yourself in our full research report (it’s free).

Our Favorite Stocks Right Now

ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.

Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.